UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more

follow us on twitter

Latest Announcements


Tina Liu

UCL alumna awarded Professional Achievement Award by British Council

Tina Liu (UCL Centre for Transport Studies, 2010) has been announced as the winner of this year’s Professional Achievement Award in the Education UK Alumni Awards for China run by the British Council. More...


Could this UCL alumnus be the next Mark Zuckerberg?

Julia Pimentel interviews Ricardo Mighty, UCL Alumnus and founder of PinU More...

Tim Barnes, Director of UCL Advances

UCL Advances Director Timothy Barnes recognised for contribution to supporting entrepreneurs in Maserati 100 list

Director of UCL Advances Timothy Barnes has been included on the Maserati 100 list in recognition of his contribution to supporting the next generation of budding entrepreneurs and growing small businesses. The list was prepared by the independent Centre for Entrepreneurs in partnership with the Sunday Times. More...



Entrepreneurship Guest Lecture Series - Alicia Navarro, Skimlinks

What’s life like as an entrepreneur? Find out about the highs and lows of the entrepreneurial journey from our inspirational guest speakers, all leading figures in entrepreneurship and investment. More...


Invitation to UCL Division of Medicine 'Employer Engagement' event

Special guest speaker, Peter Ellingworth, Chief Executive of ABHI.


Self-Management, Branding & Decision Making (ESM)

Trainer: Stuart Maddocks [] More...


London is a scientific powerhouse – and it’s about more than Nobel Prizes

By Stephen Caddick, Vice-Provost (Enterprise) at UCL
THE AWARD of the Nobel Prize in Physiology or Medicine this week to London-based professor John O’Keefe, along with his colleagues Moser and Moser, is well-deserved recognition for truly ground-breaking science – science which, in time, could have profound ramifications for the way we understand and treat neurological diseases like Alzheimer’s.

Market success for university research

The recent success of Imperial College in realising £10m cash in exchange for a 10 per cent share holding in Imperial Innovations shows the continued market interest in the commercialisation of university research (report, 24 June).

Letters to the Editor - 17/03 - Science startups, Best of Twitter

[Re: Why Britain’s scientists are failing at business, Friday]
Tim Farron is right to highlight some of the challenges facing all entrepreneurs in this country, but the idea that Britain’s scientific community is failing at business is simply not accurate. More...